Publicaciones

Resultados de 1117 a 1128 de 2201
8 febrero 2017
Administración de terapia con metadona para trastornos de uso de opioides en Rusia: análisis de coste-eficacia

Administración de terapia con metadona para trastornos de uso de opioides en Rusia: análisis de coste-eficacia

Un estudio del Boston Medical Center revela que administrar terapia con metadona para tratar los desórdenes por uso de opioides en los centros de atención que funcionan en Rusia es una medida con una buena relación entre coste y eficacia. Más información, en inglés, está disponible abajo. Suscríbase a las Alertas mensuales del IDPC para recibir información sobre cuestiones relacionadas con políticas sobre drogas. Background: Opioid agonist therapy using methadone, an effective treatment of opioid use disorders (OUD) for people who inject drugs (PWID), is recommended by the World Health Organization as essential to curtail the growing HIV epidemic. Yet, despite increasing prevalence of OUD and HIV, methadone therapy has not yet been implemented in Russia. The aim of this modeling study was to estimate the cost-effectiveness of methadone therapy for Russian adults with a diagnosed OUD. Methods/Design: We modeled the projected program implementation costs and estimated disability-adjusted life years (DALYs) averted over a 10-year period, associated with the provision of methadone therapy for a hypothetical, unreplenished cohort of Russian adults with an OUD (n = 249,000), in comparison to the current therapies at existing addiction treatment facilities. Our model compared four distinct scenarios of treatment coverage in the cohort ranging from 3.1 to 55%. Results: Providing methadone therapy to as few as 3.1% of adults with an OUD amounted to an estimated almost 50,000 DALYs averted over 10 years at a cost of just over USD 17 million. Further expanding service coverage to 55% resulted in an estimated almost 900,000 DALYs averted, at a cost of about USD 308 million. Conclusion: Our study indicated that implementing opioid agonist therapy with methadone to treat OUD at existing facilities in Russia is highly cost-effective. Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.
8 febrero 2017
Reducción de la oferta de drogas: panorámica de leyes y medidas en la UE

Reducción de la oferta de drogas: panorámica de leyes y medidas en la UE

El Observatorio Europeo de las Drogas y las Toxicomanías (OEDT) analiza las políticas y las respuestas de la UE a la producción y el tráfico de drogas ilícitas en todo el mundo. Más información, en inglés, está disponible abajo. Suscríbase a las Alertas mensuales del IDPC para recibir información sobre cuestiones relacionadas con políticas sobre drogas. The operation of illicit drug markets is dependent on a chain of events with a global span. At each stage of the process, from the production to the trafficking through to the consumption and the derived profits, the health and security of different countries is compromised by organised crime groups. This paper looks at EU policies and responses to the production and trafficking of illicit drugs, set within the global context. It considers the different strategic areas where these challenges are addressed, the EU structures involved, and some of the key measures currently being implemented by the EU and its international partners. Drug supply reduction issues arise in many policy areas, including illicit drug policy, security, organised crime, and maritime and regional cooperation policy. Issues related to drug production and trafficking arise in the work of several institutions, bodies and EU agencies. The operation of smuggling routes challenges the security of the EU in different ways and measures have been adopted to counteract these problems. These include developing intelligence-led policing and improved border management and surveillance as well as legislative tools to target criminal profits. The EU is involved in a range of projects and initiatives around the world designed to reduce the supply of illicit drugs, including capacity-building initiatives targeting smuggling routes and measures to support economic, legislative and monitoring infrastructural development. Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.